Danny Nguyen, M.D.
Location
Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Seacliff
Huntington Beach, CA 92648
Education & Experience
2016, American Board of Hematology
2016, American Board of Medical Oncology
2013, American Board of Internal Medicine
2010, Doctor of Medicine, University of South Florida, Tampa, FL
2006, Bachelor of Science, Molecular and Microbiology, University of Central Florida, Orlando, FL
2016, Hematology-Oncology, H. Lee Moffitt Cancer Center,
University of South Florida, Tampa, FL
2013, Internal Medicine, Emory School of Medicine, Atlanta, GA
2011, Internal Medicine, Emory School of Medicine, Atlanta, GA
2021-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Huntington Beach and Irvine, CA
2016-2021, Hematologist-Oncologist, Pacific Shores Medical Group, Huntington Beach
and Irvine, CA
Awards & Memberships
Awards
2015, Winner, Moffitt Symposium,
In collaboration with Jason Brayer for: A novel role for
histone deacetylase 11 (HDAC 11) B cell lymphopoiesis
and plasma cell survival in multiple myeloma
Memberships
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Publications
- Piotrowska Z, Tan DS, Smit EF, Spira AI, Soo RA, Nguyen D, Lee VH, Yang JC, Velcheti V, Wrangle JM, Socinski MA, Koczywas M, Janik JE, Jones J, Yu HA. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. J Clin Oncol. 2023 Jun 29:JCO2300152. doi: 10.1200/JCO.23.00152. Epub ahead of print. PMID: 37384848.
- Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761.
- Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 Jul;11(7):1688-1699. doi: 10.1158/2159-8290.CD-20-1598.
- Mahipal A, Nguyen D, Risk and Benefits of Phase I Clinical Trial Participation. Cancer Control. Vol. 21, No. 3, July 2014. Page 193-199
- Villagra A, Wang H-W, Nguyen D, Sotomayor EMS, et al. The histone deacetylase HDAC 11 regulates the expression interleukin 10 and immune tolerance. Nature Immunology. Vol.10, No. 1, January 2009. Page 92-100.